FBXW28, a crucial component of the ubiquitin-proteasome system, is regulated and activated by a range of chemical compounds, each influencing specific signaling pathways that culminate in enhanced activity of FBXW28. Forskolin, for example, increases intracellular cAMP levels, activating PKA, which can phosphorylate substrates in the ubiquitination process, thus indirectly enhancing the activity of FBXW28. Similarly, MG132 and Bortezomib, both proteasome inhibitors, lead to an accumulation of ubiquitinated proteins. This accumulation indirectly necessitates increased activity of FBXW28 to manage the heightened demand for protein degradation. Epigallocatechin gallate, acting as a kinase inhibitor, indirectly enhances FBXW28 activity by reducing competitive kinase activity, thus influencing the ubiquitination process more favorably for FBXW28. LY294002 and Wortmannin, both PI3K inhibitors, reduce AKT phosphorylation and activity, leading to an environment where FBXW28's role in ubiquitination becomes more prominent due to decreased AKT-mediated survival signaling.
Furthermore, the functional dynamics of FBXW28 are intricately influenced by compounds like Rapamycin, SB203580, U0126, and Thapsigargin, each playing a unique role in enhancing FBXW28 activity. Rapamycin, through mTOR inhibition, shifts the cellular balance towards protein degradation, thus indirectly enhancing the ubiquitination role of FBXW28. SB203580, a p38 MAPK inhibitor, and U0126, a MEK1/2 inhibitor, alter signaling pathways in a way that favors FBXW28's involvement in protein turnover and degradation. Thapsigargin, by increasing cytosolic calcium levels, activates calcium-dependent enzymes and pathways, indirectly enhancing the ubiquitination process where FBXW28 is a key player. Lastly, Staurosporine, a broad-spectrum kinase inhibitor, enhances FBXW28 activity by reducing kinase-mediated competition in the ubiquitin-proteasome pathway, thus allowing FBXW28 to more effectively target proteins for degradation. Collectively, these compounds, through their targeted effects on cellular signaling, facilitate the enhancement of FBXW28-mediated functions, emphasizing its role in the critical process of protein ubiquitination and degradation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Increases intracellular cAMP, activating PKA, which enhances FBXW28's activity in protein ubiquitination by phosphorylating substrates within the ubiquitin-proteasome system. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that causes ubiquitinated proteins' accumulation, indirectly enhancing FBXW28's role in ubiquitin-mediated protein degradation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Acts as a kinase inhibitor, reducing competitive kinase activity, thus indirectly enhancing FBXW28's activity in the ubiquitin-proteasome pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that reduces AKT activity, leading to enhanced FBXW28 activity in protein ubiquitination due to decreased AKT-mediated survival signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTOR, altering the balance of protein synthesis and degradation, indirectly enhancing FBXW28's ubiquitination role due to increased need for proteasomal degradation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that indirectly enhances FBXW28 activity by altering signaling pathways that regulate protein turnover, where FBXW28 is involved. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Inhibits MEK1/2 in the MAPK pathway, shifting focus towards degradation pathways and enhancing FBXW28's activity in the ubiquitin-proteasome system. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Similar to LY294002, this PI3K inhibitor reduces AKT phosphorylation and activity, enhancing FBXW28's ubiquitination activity by making more substrates available for ubiquitination. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
A SERCA inhibitor that increases cytosolic calcium levels, indirectly enhancing FBXW28 activity in protein ubiquitination through calcium-dependent signaling pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Another proteasome inhibitor leading to ubiquitinated proteins' accumulation, enhancing FBXW28's functional activity in targeting proteins for ubiquitination. | ||||||